— New therapeutic candidate developed using Company's patented ThermoStem® platform — — Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and marketed towards weight loss — — DMF submission and commencement of first-in-human studies targeted for before the end of 2024 — — Expanding the use of ThermoStem® may open the door to big pharma partnership opportunities — MELVILLE, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", ...